Prevention of human papillomavirus infections and associated diseases by vaccination: A new hope for global public health

Public Health Genomics

Volumn 12, Issue 5-6, 2009, Pages 319-330

  Harper, Diane M ^a,b  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b TRUMAN MEDICAL CENTER   (United States)

Author keywords

Cervical cancer; Cervical dysplasia; Immunogenicity; Vaccine, HPV, efficacy; Vaccine, HPV, safety; Vulvovaginal dysplasia

Indexed keywords

PLACEBO; SILGARD; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANUS CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG INHIBITION; EPITHELIUM CELL; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MOUTH CANCER; MYELITIS; OROPHARYNX CANCER; PENIS CANCER; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VACCINATION; VAGINA CANCER; VIRION; VIRUS INFECTION; VULVA CANCER; WART VIRUS;

ADOLESCENT; ADULT; CANCER VACCINES; DRUG APPROVAL; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; UNITED STATES; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINAL DISEASES; VULVAR DISEASES;

HUMAN PAPILLOMAVIRUS;

EID: 69249128375     PISSN: 16624246     EISSN: None     Source Type: Journal    
DOI: 10.1159/000214922     Document Type: Review

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. de Sanjose S, Tous S, on behalf of RIS HPV TT study group: Worldwide HPV genotype distribution in 10,289 cases of cervical cancer. 24th Intl Papillomavirus Conf, Beijing, November 2007.
3. Castellsagué X, Bosch FX, Muñoz N, et al: Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346: 1105-1112.
4. Joura EA, Leodolter S, Hernandez-Avila M, et al: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693-1702.
5. www.fda.gov/cber/products/gardasil/gardasil091108. pdf (accessed February 9, 2009).
6. Harper DM, Franco EL, Wheeler CM, et al. for the GlaxoSmithKline HPV Vaccine Study Group: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-1765.
7. Villa LL, Costa RL, Petta CA, et al: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278.
8. Harper DM: High and sustained protection up to 6.4 years with GSK's AS04 adjuvanted cervical cancer vaccine. SocGynecologic Oncol Meet, Tampa, March 2008.
9. Olsson SE, Villa LL, Costa RLR, et al: Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 2: 4931-4939.
10. Clifford G, Smith JS, Aguado T, Franceschi S: Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 101-105.
11. Koutsky LA for the FUTURE II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
12. Garland SM, Hernandez-Avila M, Wheeler CM, et al: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943.
13. Harper DM, Franco EL, Wheeler CM, et al. for the GlaxoSmithKline HPV Vaccine Study Group: Sustained efficacy up to 4•5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255.
14. Kalliala I, Anttila A, Pukkala E, Nieminen P: Risk of cervical and other cancers after treatment of CIN. BMJ 2005; 331: 1183-1185.
15. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR: Costa Rican HPV Vaccine Trial Group: Effect of human papillomavirus 16/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298: 743-753.
16. Paavonen J, Jenkins D, Bosch FX, et al: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-2170.
17. Cruickshank M, Teixeira J, Gall S, et al: Efficacy and safety for GSK's HPV vaccine in women initially seropositive or seronegative for HPV 16/18 in a phase III trial. EuroGin, Monte Carlo, October 2007.
18. Kim D, Gambhira R, Karanama B, et al: Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine 2008;26:351-360.
19. Garcea RL: New vaccines for the prevention and treatment of human papillomavirus infection. EuroGin Nice, 2008.
20. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, Koutsky LA: Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191: 731-738.
21. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, Miller S, Canjura- Clayton KL, Farhat S, Broering JM, Darragh TM: Regression of low-grade squamous intra- epithelial lesions in young women. Lancet 2004; 364: 1678-1683.
22. Villa LL, Ault KA, Giuliano AR, et al: Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006; 24: 5571-5583.
23. Poland GA, Jacobson RM, Koutsky LA, et al: Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clin Proc 2005; 80: 601-610.
24. Block SL, Nolan T, Sattler C, et al: Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118: 2135-2145.
25. Giannini SL, Hanon E, Moris P, et al: Enhanced humoral and memory B cellular immunity using HPV 16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24: 5937-5949.
26. Caluger A, et al: Quadrivalent human papillomavirus vaccine (HPV4): post licensure safety update. Vaccine adverse event reporting system (VAERS) United States. ACIP meeting, October 2008. www.cdc.gov/vaccines/ recs/acip/slides- oct08.htm#hpv (accessed February 9, 2009).
27. Brotherton JM, Gold MS, Kemp AS, et al; New South Wales Health HPV Adverse Events Panel: Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 2008; 179: 525-533.
28. Slade B, et al: Clinical Immunization Safety Assessment (CISA) Network: October 2008 ACIP meeting, October 2008. www.cdc.gov/ vaccines/recs/acip/slides- oct08.htm#hpv (February 9, 2009).
29. Wheeler CM, Bautista OM, Tomassini JE, et al: Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV) -6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008; 26: 686-696.
30. Schwarz TF, et al: Co-administration of GSK's AS04 adjuvanted cervical cancer vaccine with combined dTpa-IPV vaccine in girls aged 10-18 years. Presented at ICID, Kuala Lumpur, 2008, 19-026. www.isid.org/downloads/13th-ICID- AbsPosters.pdf (accessed May 18, 2009).
31. Shaneyfelt TM, Centor RM: Reassessment of clinical practice guidelines: go gently into that good night. JAMA 2009; 301: 868-869.
32. Barnabas RV, Laukkanen P, Koskela P, et al: Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006; 3:e138.
33. Goldie SJ, Kohli M, Grima D, et al: Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-615.
34. Kulasingam SL, Myers ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290: 781-789.
35. Chesson HW, et al: Cost effectiveness models of HPV vaccines. National STD Prevention Conference, May 2006.
36. Kim JJ, Goldie SJ: Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359: 821-832.
37. Edgren G, Sparén P: Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol 2007; 8: 311-316.
38. Ault KA for The Future II Study Group: Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-1868.
39. Harper DM: Bivalent Vaccine. EuroGin, Monte Carlo, October 2007.
40. Wheeler CM for the HPV Vaccine Study Group: High and sustained HPV-16 and 18 antibody levels through 6.4 years in women vaccinated with Cervarix™ (GSK HPV-16/18 AS04 vaccine). Presented at: ESPID, Graz, May 2008. www.kenes.com/espid2008/program/ search.asp (accessed February 9, 2009).
41. Paavonen J for the HPV PATRICIA Study Group: Final phase III efficacy analysis of Cervarix in young women. Presented at IPV Malmo, Sweden, May 2009, O-29.06.
42. Skinner R for HPV PATRICIA Study Group: Cross-protective efficacy of Cervarix against oncogenic HPV types beyond HPV 16/18. Presented at IPV, Malmo, Sweden, May 2009, O-29.01.
43. Einstein MH for the HPV 010 Study Group: Immune response after primary vaccination course: A comparative trial of two HPV prophylactic vaccines. Presented at IPV, Malmo, Sweden, May 2009, O-01.02.
44. Muñoz N, Manalastas R Jr, Pitisuttithum P, et al: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, doubleblind trial. Lancet 2009;373:1949-1958.
45. Rodriguez A for NCI Guanacaste Cohort study: Imputed global vaccination benefit by key risk predictors. Presented at IPV, Malmo, Sweden, May 2009, O-01.05.
46. Brown DR et al: The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199:926-935.
47. Herrero R: Human papillomavirus (HPV) vaccines: Limited cross-protection against additional HPV types. J Infect Dis 2009; 199:919-922.